News Release：2024 | Eisai Co., Ltd.
Oct 4, 2024 · eisai completes a major renovation of tsukuba research laboratories as a global drug discovery center aiming for connecting human and human, and data, and the world. april 4, 2023. eisai publishes long-term health outcomes using simulation model of lecanemab using phase 3 clarity ad data in peer-reviewed neurology and therapy journal
FDA Approves LEQEMBI™ (lecanemab-irmb) Under the ... - Eisai …
Jan 7, 2023 · FDA Approves LEQEMBI™ (lecanemab-irmb) Under the Accelerated Approval Pathway for the Treatment of Alzheimer’s Disease. Accelerated Approval is based on Phase 2 data showing a reduction in amyloid-beta plaques in early AD patients treated with LEQEMBI™. Treatment with LEQEMBI should be initiated in patients with mild cognitive impairment ...
EISAI PRESENTS FULL RESULTS OF LECANEMAB PHASE 3 …
Nov 30, 2022 · Design of Clarity AD Study. Eisai’s Clarity AD was a global confirmatory Phase 3 placebo-controlled, double-blind, parallel-group, randomized study in 1,795 people with early AD (lecanemab group: 898 placebo group: 897) at 235 sites in North America, Europe, and Asia.
Latest News - Eisai Co., Ltd.
Aug 2, 2024 · IR “First Quarter Financial Results Briefing for the Fiscal Year Ending March 31, 2025 [Material, Webcast]”. August 2, 2024.
Notification of Ransomware Incident | News Release：2023 - Eisai …
Jun 6, 2023 · A ransomware incident that encrypted some of Eisai Group’s servers was detected late night on Saturday, June 3, Japan time. We immediately implemented our incident response plan and launched an investigation with the aid of our cybersecurity partners.
Media center - recent news, blogs, and articles | Eisai US
6 days ago · Eisai's media center is where you’ll find breaking news, press releases, as well as blogs and articles about the company, our people, and our innovations.
A research-based pharmaceutical company | Eisai US
Eisai Completes Rolling Submission to US FDA for LEQEMBI® (lecanemab-irmb) Biologics License Application for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer's Disease Under the Fast Track Status. Read more >. Press Release. October 30, 2024.
New Clinical Data Demonstrates Three Years of ... - Eisai Co., Ltd.
Jul 31, 2024 · More than 50% of Patients Who Started Treatment in the Earliest Stage of AD Continued to Show Improvement After Three Years of Lecanemab Treatment. The Clarity AD study included an optional tau PET substudy and used the tau PET probe MK6240 to identify patients with no tau or a low accumulation of tau in the brain.
EISAI ANNOUNCES MOVE TO SOLO DEVELOPMENT AND …
Jul 1, 2024 · Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) announced today that it has agreed to end its global strategic collaboration with Bristol Myers Squibb for the co-development and co-commercialization of farletuzumab ecteribulin (FZEC), formerly known as MORAb-202, a folate receptor alpha (FRα)-targeting antibody drug ...
FDA Approves LEQEMBI™ (lecanemab-irmb) Under the ... - Eisai …
Jan 6, 2023 · Eisai announced the U.S. pricing and rationale for LEQEMBI today. Eisai serves as the lead of LEQEMBI development and regulatory submissions globally with both Eisai and Biogen co-commercializing and co-promoting the product and Eisai having final decision-making authority. * Protofibrils are large Aβ aggregated soluble species of 75-500 Kd. 1, 2